Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607146 | 0.87 | TDP1 (0.42) | SLC6A2SLC6A4SLC6A3TDP1TSHR | |
| SCHEMBL6224183 | 0.82 | ALDH1A1 (0.40) | AOC3IDO1TDO2SLC6A2SLC6A4 | |
| SCHEMBL28429634 | 0.79 | HTR7 (0.39) | SLC6A2SLC6A4SLC6A3MAPK1LMNA | |
| SCHEMBL11540646 | 0.78 | GRM2 (0.41) | TSHRLMNAALDH1A1 | |
| SCHEMBL9398857 | 0.78 | ALDH1A1 (0.43) | IDO1SLC6A2SLC6A3ACHETDP1 | |
| SCHEMBL6203092 | 0.78 | TSHR (0.48) | AOC3IDO1TDO2SLC6A2SLC6A4 | |
| SCHEMBL21831332 | 0.77 | IDO1 (0.40) | AOC3IDO1TDO2SLC6A2SLC6A4 | |
| SCHEMBL6187725 | 0.76 | TRPA1 (0.41) | AOC3IDO1TDO2LMNAHTT | |
| SCHEMBL20868530 | 0.76 | CES2 (0.33) | IDO1TDO2 | |
| SCHEMBL4599672 | 0.76 | TRPA1 (0.41) | AOC3IDO1TDO2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332699-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SAGE THERAPEUTICS, INC. | 2022-10-20 | — | — | US | disclosed |
| EP-3976186-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Sage Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243027-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| EP-1194404-A1 | INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000076961-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-12-21 | — | — | WO | disclosed |
| US-4051190-A | MANUFACTURE OF 3-ARYLPROPYL CHLORIDE | ABBOTT LABORATORIES (US) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332699-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYP46A1, CYP26A1, CYP21A2 | AOC3 352/4885IDO1 1329/4885TDO2 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.